BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 207.00
-1.60 (-0.77%)
Sep 10, 2026, 4:08 PM HKT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.71B USD in the quarter ending June 30, 2026, with 29.63% growth. This brings the company's revenue in the last twelve months to $6.13B, up 34.35% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth.
Revenue (ttm)
$6.13B
Revenue Growth
+34.35%
P/S Ratio
6.51
Revenue / Employee
$510.75K
Employees
12,000
Market Cap
312.97B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| WuXi Biologics | 27.27B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| RemeGen | 9.24B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Akeso | 3.98B |
BeOne Medicines AG News
- 12 hours ago - BeOne Medicines price target raised to $415 from $407 at Barclays - TheFly
- 9 days ago - BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference - Business Wire
- 10 days ago - Trump Administration Reaches Drug Pricing Deals With 9 Companies - WSJ
- 10 days ago - BeOne Medicines to expand access to cancer medicines under pact with U.S. - TheFly
- 10 days ago - BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Business Wire
- 10 days ago - BeOne Medicines announces new Phase 3 survival data on Ziihera - TheFly
- 10 days ago - BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer - Business Wire
- 14 days ago - BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy? - Nasdaq